Hemispherx Biopharma Featured in Corporate America News Magazine Special Report “Capturing the Power of Immune Response to Treat Disease: Biotech Bounce Back”
08. November 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) has posted an article from Corporate America News magazine, released on...
A Hemispherx Biopharma anuncia um grande avanco: A aprovacão para comercializar o rintatolimode (nome comercial nos Estados Unidos: Ampligen®) para o tratamento de casos graves de Encefalomielite Miálgica/Síndrome da Fadiga Crônica (EM/SFC) na República Argentina
26. August 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
O primeiro produto aprovado indicado para EM/SFC em qualquer parte do mundo Essa aprovação inédita significa um caminho aberto para o crescimento na América Latina e União Europeia ...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
26. August 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 26, 2016 (GLOBE...
Hemispherx Biopharma anuncia un logro importante: aprobación de rintatolimod para la venta comercial (nombre comercial en EE. UU.: Ampligen®) para el tratamiento de casos severos de encefalomielitis miálgica/síndrome de fatiga crónica (EM/SFC) en la República Argentina
26. August 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
Primer producto aprobado para la indicación EM/SFC en todo el mundo Esta nueva aprobación abre paso para el crecimiento en Latinoamérica y la Unión Europea PHILADELPHIA, Aug. 26, 2016 (GLOBE...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
26. August 2016 01:00 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 26, 2016 (GLOBE...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
25. August 2016 20:30 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 25, 2016 (GLOBE...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
24. August 2016 10:03 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 24, 2016 (GLOBE...